Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07701941 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer

Name: A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer — clinical trial record (NCT07701941)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 1/2

SponsorDaiichi Sankyo

Started2026-09-17

View on ClinicalTrials.gov ↗

Amendment history

2026-10-02

Recruitment opened

Trial sites expanded: 0 → 72 locations

Daiichi Sankyo

69 trials monitored

See 8 trials at risk

Breast Cancer

5,180 trials monitored

See 256 trials at risk

The primary purpose of the study is to assess the safety, tolerability, and anti-tumor activity of HER3-DXd and T-DXd in the combination dosing regimens in participants with hormone receptor positive, HER2-low or HER2-ultralow, unresectable, or metastatic breast cancer.

Trial Details

NCT Number	NCT07701941
Lead Sponsor	Daiichi Sankyo Collaborators: Merck Sharp & Dohme LLC
Conditions	Hormone Receptor Positive, HER2-low or HER2-ultralow, Unresectable or Metastatic Breast Cancer
Enrollment	220 participants
Start Date	2026-09-17
Primary Completion	2031-01-01 (estimated)
Study Completion	2032-05-01 (estimated)
Updated on ClinicalTrials.gov	2026-10-01